Sabra Healthcare REIT (SBRA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Sabra Healthcare REIT is set to announce its Q3 2025 earnings on October 30th, with expectations of earnings at $0.38 per share and revenue of approximately $193.4 million.
• The company recently declared a quarterly dividend of $0.30 per share, translating to a 6.6% yield and a high dividend payout ratio of 157.89%.
• Analysts have mixed ratings on the stock, with a consensus target price of $20.75; reports suggest one analyst rates it as a Strong Buy and several others have given varying ratings from Buy to Hold.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) is expected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $193.4360 million for the quarter. Sabra Healthcare REIT has set its FY 2025 guidance at 1.450-1.470 EPS.Parties are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 1:00 PM ET.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last issued its earnings results on Monday, August 4th. The real estate investment trust reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.02. Sabra Healthcare REIT had a net margin of 24.87% and a return on equity of 6.69%. The firm had revenue of $189.15 million during the quarter, compared to analysts' expectations of $185.64 million. During the same quarter last year, the company posted $0.36 earnings per share. The firm's revenue was up 7.4% compared to the same quarter last year. On average, analysts expect Sabra Healthcare REIT to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Sabra Healthcare REIT Trading Up 0.8%

Shares of Sabra Healthcare REIT stock opened at $18.25 on Thursday. The company has a debt-to-equity ratio of 0.91, a current ratio of 4.80 and a quick ratio of 4.80. The firm has a fifty day moving average price of $18.66 and a 200 day moving average price of $18.20. Sabra Healthcare REIT has a 1 year low of $15.60 and a 1 year high of $20.03. The stock has a market cap of $4.38 billion, a PE ratio of 24.01, a price-to-earnings-growth ratio of 1.15 and a beta of 0.85.

Sabra Healthcare REIT Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Friday, August 15th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 6.6%. The ex-dividend date was Friday, August 15th. Sabra Healthcare REIT's dividend payout ratio (DPR) is currently 157.89%.

Institutional Investors Weigh In On Sabra Healthcare REIT

Large investors have recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. increased its stake in Sabra Healthcare REIT by 3.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 83,889 shares of the real estate investment trust's stock worth $1,547,000 after buying an additional 2,557 shares during the period. Diversify Advisory Services LLC grew its position in Sabra Healthcare REIT by 488.7% during the 2nd quarter. Diversify Advisory Services LLC now owns 75,811 shares of the real estate investment trust's stock worth $1,412,000 after purchasing an additional 62,933 shares during the last quarter. Captrust Financial Advisors grew its position in Sabra Healthcare REIT by 20.4% during the 2nd quarter. Captrust Financial Advisors now owns 60,371 shares of the real estate investment trust's stock worth $1,113,000 after purchasing an additional 10,235 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Sabra Healthcare REIT by 213.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 41,770 shares of the real estate investment trust's stock worth $770,000 after purchasing an additional 28,448 shares during the last quarter. Finally, Gallagher Fiduciary Advisors LLC grew its position in Sabra Healthcare REIT by 22.2% during the 2nd quarter. Gallagher Fiduciary Advisors LLC now owns 31,658 shares of the real estate investment trust's stock worth $584,000 after purchasing an additional 5,756 shares during the last quarter. 99.40% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SBRA has been the subject of a number of research reports. Truist Financial boosted their target price on shares of Sabra Healthcare REIT from $18.00 to $20.00 and gave the stock a "hold" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company reduced their target price on shares of Sabra Healthcare REIT from $21.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday. National Bankshares set a $22.00 target price on shares of Sabra Healthcare REIT in a research note on Friday, October 17th. JMP Securities boosted their price target on shares of Sabra Healthcare REIT from $20.00 to $22.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Sabra Healthcare REIT in a research note on Wednesday, October 1st. They issued a "neutral" rating and a $20.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Sabra Healthcare REIT has an average rating of "Moderate Buy" and a consensus target price of $20.75.

About Sabra Healthcare REIT

Sabra Health Care REIT, Inc engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.